357 related articles for article (PubMed ID: 32014610)
1. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
[TBL] [Abstract][Full Text] [Related]
2. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract][Full Text] [Related]
3. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
4. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
[TBL] [Abstract][Full Text] [Related]
5. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.
Moore DA; Benafif S; Poskitt B; Argue S; Lee SM; Ahmad T; Papadatos-Pastos D; Jamal-Hanjani M; Bennett P; Forster MD
Lung Cancer; 2021 Nov; 161():55-59. PubMed ID: 34536732
[TBL] [Abstract][Full Text] [Related]
6. Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer.
Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W
Intern Med J; 2024 Apr; 54(4):596-601. PubMed ID: 37713593
[TBL] [Abstract][Full Text] [Related]
7. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
Li W; Liu Y; Li W; Chen L; Ying J
J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
[TBL] [Abstract][Full Text] [Related]
8. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
Brisudova A; Skarda J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
[TBL] [Abstract][Full Text] [Related]
9. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.
Xie F; Zheng X; Mao X; Zhao R; Ye J; Zhang Y; Sun J
Ann Thorac Surg; 2019 Jul; 108(1):219-226. PubMed ID: 30885850
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Davies KD; Le AT; Sheren J; Nijmeh H; Gowan K; Jones KL; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2018 Oct; 13(10):1474-1482. PubMed ID: 29935306
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
Dall'Olio FG; Conci N; Rossi G; Fiorentino M; De Giglio A; Grilli G; Altimari A; Gruppioni E; Filippini DM; Di Federico A; Nuvola G; Ardizzoni A
Lung Cancer; 2020 Nov; 149():5-9. PubMed ID: 32932213
[TBL] [Abstract][Full Text] [Related]
13. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
[TBL] [Abstract][Full Text] [Related]
14. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
15. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
16. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.
Ju S; Cui Z; Hong Y; Wang X; Mu W; Xie Z; Zeng X; Su L; Lin X; Zhang Z; Zhang Q; Song X; You S; Chen R; Chen W; Xu C; Zhao J
Cancer; 2023 Aug; 129(15):2422-2430. PubMed ID: 37096747
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
18. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
[TBL] [Abstract][Full Text] [Related]
19. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
20. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
